Fox Chase Cancer Center News

“We’re dealing with lung cancer and our lung cancer patients may be more at risk for severe disease due to COVID-19. A lot of the management we do puts them at greater risk after that,” said Sameera Kumar, MD, one of the authors on the paper and an assistant professor in the Department of Radiation Oncology.
July 1, 2020

Fox Chase Researchers Help Identify Best Practices for Cancer Patient Care During COVID-19

PHILADELPHIA (July 1, 2020)—Researchers at Fox Chase Cancer Center were part of a national team that published a paper identifying best practices for facilities to protect vulnerable cancer patients during the COVID-19 pandemic.

Dr. J.K. Wong
July 1, 2020

Fox Chase Researchers Look at Toxicity, Outcomes in Determining Treatments for Older Patients With Rectal Cancer

PHILADELPHIA (July 1, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that factors other than just age can be useful in determining courses of treatment for older patients with locally advanced rectal cancer.

Jeffrey M. Farma, MD, FACS, one of the study’s authors
June 29, 2020

Study by Fox Chase Researchers Indicates Gene Mutations From UV Exposure May Play Role in Melanoma Malignancy

PHILADELPHIA (June 29, 2020)—Researchers at Fox Chase Cancer Center recently conducted a study analyzing the impact of sun exposure and tanning patterns on gene mutations in patients with advanced melanoma. Those who experienced blistering sunburn had a higher number of gene mutations in their tumors compared to those who did not experience blistering sunburn.

June 25, 2020

Fox Chase Cancer Center’s Radiation Oncology Residency Program Receives Accreditation

PHILADELPHIA (June 25, 2020) – The Accreditation Council for Graduate Medical Education (ACGME) review committee stated that the program “demonstrated outstanding compliance with the ACGME’s Program Requirements and/or Institutional Requirements.” ACGME would not require a site visit for the next 10 years, the longest duration allowed by the ACGME.

Jeffrey Chang-Jen Liu, MD, FACS
June 25, 2020

Fox Chase Researchers Explore Racial Disparities in Survival for Head and Neck Cancer Patients

PHILADELPHIA (June 25, 2020)—Survival rates for Black patients were worse than those for white patients being treated for head and neck cancer even when they had access to the same care. The researchers said the disparities could be explained by biological differences between the two groups.

Carolyn Y. Fang, PhD
June 22, 2020

Fox Chase Researchers Receive Grant to Study Approaches for Empowering Asian American Women in Cervical Cancer Screening

PHILADELPHIA (June 22, 2020)—Carolyn Y. Fang, PhD, was recently awarded a grant for the first large-scale study evaluating a method that allows Asian American women to collect their own samples, which can then be tested for the presence of the human papilloma virus (HPV). Fang will be conducting the research with Grace X. Ma, PhD, multiple principal investigator for the study.

June 18, 2020

Fox Chase Researchers Identify Possible Biomarkers in Bladder Cancer Patients Receiving Therapy Before Surgery

PHILADELPHIA (June 18, 2020)—In a recent study, researchers at Fox Chase Cancer Center found that muscle-invasive bladder cancer patients with specific gene mutations have better survival outcomes when treated with chemotherapy before surgery. The five-year survival rate for patients with at least one mutation was 85 percent, compared to 45 percent for patients without a mutation.

FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration
June 17, 2020

Fox Chase-Temple University Hospital Bone Marrow Transplant Program Awarded FACT Reaccreditation

PHILADELPHIA (June 17, 2020) – The Fox Chase-Temple University Hospital Bone Marrow Transplant Program has been reaccredited for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation. Also included is a new accreditation for immune effector cells.


Connect with Fox Chase